Abatacept
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Abatacept |
| DrugBank ID | DB01281 |
| Brand Names (EU) | Orencia |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.91% |
Approved Indication (EMA)
Rheumatoid arthritisOrencia, in combination with methotrexate, is indicated for: the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX) or a tumour necrosis factor (TNF)-alpha inhibitor. the treatment of highly active and progressive disease in adult patients with rheumatoid arthritis not previously treated with methotrexate
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | rheumatoid vasculitis | 99.91% | DL |
| 2 | ankylosing spondylitis | 99.91% | DL |
| 3 | hypermobility of coccyx | 99.87% | DL |
| 4 | inflammatory spondylopathy | 99.84% | DL |
| 5 | Kummell disease | 99.84% | DL |
| 6 | polyarticular juvenile rheumatoid arthritis | 99.83% | DL |
| 7 | rheumatoid arthritis | 99.77% | DL |
| 8 | vertebral disease | 99.68% | DL |
| 9 | spondyloarthropathy, susceptibility to | 99.65% | DL |
| 10 | brachydactyly-syndactyly syndrome | 99.50% | DL |
| 11 | colobomatous microphthalmia-rhizomelic dysplasia syndrome | 99.48% | DL |
| 12 | WHIM syndrome | 99.34% | DL |
| 13 | juvenile idiopathic arthritis | 99.31% | DL |
| 14 | rheumatoid nodulosis | 99.08% | DL |
| 15 | rheumatoid factor-positive polyarticular juvenile idiopathic arthritis | 99.07% | DL |
| 16 | juvenile chronic polyarthritis | 99.02% | DL |
| 17 | juvenile arthritis due to defect in LACC1 | 98.93% | DL |
| 18 | spondyloarthropathy | 98.18% | DL |
| 19 | mendelian susceptibility to mycobacterial diseases due to complete IL12B deficiency | 97.07% | DL |
| 20 | leukoplakia | 97.00% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.